Q2
ARCT — Q2 2026 Financial Report Analysis
Arcturus revenue fell 90% to $3.0M as CSL Seqirus income faded and the net loss widened to $23.8M ($0.84/share); after quarter-end it ended the CSL partnership for $12M, reclaiming KOSTAIVE, with $191.5M cash funding its cystic fibrosis and OTC programs.